The novel coronavirus, SARS-CoV-2, was first detected as a respiratory illness in December 2019 in Wuhan City, China. Since then, coronavirus disease 2019 (COVID-19) has impacted every aspect of our lives worldwide. In a time when terms such as social distancing and flattening the curve have become a part of our vernacular, it is essential that we understand what measures can be implemented to protect our patients and healthcare workers. Undoubtedly, healthcare providers have had to rapidly alter care delivery models while simultaneously acknowledging the crucial unknowns of how these changes may affect clinical outcomes. This special feature reviews strategies on how to mitigate transmission of COVID-19 in an effort to reduce morbidity and mortality associated with the disease for patients with cancer without infection, for patients with cancer with COVID-19 infection, and for the healthcare workers caring for them, while continuing to provide the best possible cancer care. [Editor’s Note: This article includes the most current information available at time of publication; however, recommendations regarding public safety and practice may change rapidly in this situation. Individuals should get the most up to date information from the CDC website.]
Submitted April 1, 2020; accepted for publication April 3, 2020.
Publication: This is an invited article from the NCCN Best Practices Committee.
Disclosures: Dr. Fonesca disclosed that he has served as a consultant for Amgen, Bristol Myers Squibb, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite, Aduro, OncoTracker, GlaxoSmithKline, and AbbVie, and is on the Scientific Advisory Board for Adaptive Biotechnologies and OncoTracker. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Correspondence: Pelin Cinar, MD, MS, Division of Medical Oncology, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, 550 16th Street, 6th Floor, Box 3211, San Francisco, CA 94143. Email: email@example.com.
WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Accessed March 27, 2020. Available at:https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)| false
Johns Hopkins University. Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Accessed March 29, 2020. Available at:https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6)| false
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. CCDC Weekly 2020;2:113–122. Available at:http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51)| false
Instituto Superiore di Sanita. Integrated surveillance of COVID-19 in Italy. Accessed March 28, 2020. Available at:https://www.epicentro.iss.it/coronavirus/bollettino/Infografica_28marzo%20ENG.pdf)| false
YuJ, OuyangW, ChuaMLK, XieC. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China [published online March 25, 2020]. JAMA Oncol, doi: 10.1001/jamaoncol.2020.0980
YuJ, OuyangW, ChuaMLK, XieC. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China [published online March 25, 2020]. JAMA Oncol, doi: 10.1001/jamaoncol.2020.0980)| false
CDC. Implementation of mitigation strategies for communities with local COVID-19 transmission. Accessed March 27, 2020. Available at:https://www.cdc.gov/coronavirus/2019-ncov/downloads/community-mitigation-strategy.pdf)| false
NCCN Best Practices Committee Infusion Efficiency Workgroup. Toolkit: providing oncology treatments in the outpatient setting. Accessed April 1, 2020. Available at:https://www.nccn.org/covid-19/pdf/NCCN_Toolkit_Updated_for_COVID-19.pdf)| false
CDC. Discontinuation of in-home isolation for immunocompromised persons with COVID-19 (interim guidance). Accessed March 27, 2020. Availabe at:https://www.cdc.gov/coronavirus/2019-ncov/hcp/ending-isolation.html)| false
CDC. Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings. Accessed April 1, 2020. Available at:https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Finfection-control.html)| false
WHO. Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19) 2020. Accessed April 1, 2020. Available at:https://apps.who.int/iris/bitstream/handle/10665/331215/WHO-2019-nCov-IPCPPE_use-2020.1-eng.pdf)| false
Emergency Use Authorization (EUA) for the emergency use of the Battelle CCDS Critical Care Decontamination System. Accessed March 31, 2020. Available at:https://www.fda.gov/media/136529/download)| false
LaiJ, MaS, WangY, . Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019 [published online March 23, 2020]. JAMA Netw Open, doi: 10.1001/jamanetworkopen.2020.3976
LaiJ, MaS, WangY, . Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019 [published online March 23, 2020]. JAMA Netw Open, doi: 10.1001/jamanetworkopen.2020.3976)| false
NCCN. Self-care and stress management during the COVID-19 crisis: toolkit for oncology health care professionals. Accessed March 26, 2020. Available at:https://www.nccn.org/covid-19/pdf/Distress-Management-Clinician-COVID-19.pdf)| false